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[Introduction] Treatments for acute myocardial infarction (MI) have improved over the past three decades, markedly 
decreasing the mortality rate of MI during the acute phase. However, the incidence of heart failure post-MI remains high. 
The goal of this study was to elucidate the molecular and cellular mechanisms involved in the progression of cardiac 
remodeling and evaluate the effects of traditional treatment with angiotensin receptor blockers or aldosterone receptor 
antagonists. Collagen synthesis and degradation are important factors in cardiac remodeling. Recent studies have shown 
that periostin can directly interact with collagen type I and plays an important role in LV remodeling after MI by 
promoting collagen synthesis. And matrix metalloproteinases (MMPs) comprise a family of zinc-dependent proteases 
responsible for extracellular matrix degradation during cardiac remodeling under normal and pathological conditions. In 
the present study, I investigated the effects of an aldosterone receptor antagonist (spironolactone) and an ARB 
(candesartan) on cardiac remodeling and evaluated the expression of periostin, MMP-1 and -2 in the non-infarcted 
myocardium of rats during the progression of heart failure after MI. 
[Methods] Eight-week-old male Wistar-Kyoto rats underwent either coronary ligation or sham operation. Rats in the 
sham-operated group were subjected to simulated surgery (SHAM group; n = 8). Echocardiography was performed 4 
weeks after MI to rule out insignificant LV dysfunction, and MI rats were assigned to four groups (n = 6–8 each): MI 
group, spironolactone group (50 mg/kg/day), candesartan group (1 mg/kg/day), and combination group. Rats were 
treated for 8 weeks. 
[Results] MI increased the expression of periostin and collagen types I and III in the non-infarcted myocardium; all 
treatments reduced the expression levels of these three proteins. Additionally, the elevated heart weights, decreased 
ejection fraction, and reduced fractional shortening were ameliorated by administration of candesartan alone or in 
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combination with spironolactone. Combined therapy had greater effects on the inhibition of periostin overexpression 
than the monotherapy. Moreover, spironolactone, but not candesartan, increased MMP-1 expression. 
[Conclusions] In summary, periostin may modulate cardiac remodeling in rats with chronic heart failure after MI. 
Combined therapy with spironolactone and candesartan may be more beneficial than individual use of these drugs. The 
beneficial effects of spironolactone and candesartan may involve attenuation of periostin expression. MMP-1 may be 
related to the effect of spironolactone on cardiac fibrosis. These results reveal that periostin is a marker 
associated with disease progression and regression in chronic cardiac remodeling after MI and suggest 
that the measurement of periostin may be a sensitive tool for evaluating the severity, progression, and 
response to therapy in human CHF associated with MI. 
 
